Author:
Kanungo Shibani,Vergano Samantha,Clark Thomas,Madani Rami,Schott Melissa,Couch Kira,Villela Rubie,White Natalie
Abstract
Krabbe disease (KD), a severe neurodegenerative disorder, has been controversial in the space of newborn screening (NBS) in the United States. Families continue to advocate for the addition of KD to the Recommended Uniform Screening Panel (RUSP) after being declined for the second time in February 2023. Even with significant progress in KD screening tests, uncertainty about the phenotypic presentations, and effectiveness of hematopoietic stem cell transplant (HSCT) seems to have impeded the addition of this condition to the RUSP. Potential in-utero onset of symptoms in early infantile onset Krabbe disease (EIKD) raise questions on the ‘pre-symptomatic’ requirement of NBS. This paper reviews the current knowledge of KD, including accepted and investigational treatments to help further the discussion for adding KD on NBS panels.
Reference65 articles.
1. Orsini JJ, Escolar ML, Wasserstein MP, Caggana M. Krabbe disease. In: GeneReviews® [Internet]. Seattle, WA: University of Washington; 2018. Available from: https://www.ncbi.nlm.nih.gov/books/NBK1238/.
2. OMIM. Krabbe disease; KRB [Internet]. Baltimore, MD: Online Mendelian Inheritance in Man; 2022 [cited date 2023 April 19]. Available from: https://omim.org/entry/245200#genotypePhenotypeCorrelations.
3. Wasserstein MP, Andriola M, Arnold G, Aron A, Duffner P, Erbe RW, et al. Clinical outcomes of children with abnormal newborn screening results for Krabbe disease in New York State. Genet Med. 2016; 18: 1235-1243.
4. Kwon JM, Matern D, Kurtzberg J, Wrabetz L, Gelb MH, Wenger DA, et al. Consensus guidelines for newborn screening, diagnosis and treatment of infantile Krabbe disease. Orphanet J Rare Dis. 2018; 13: 30.
5. Basheeruddin K, Shao R, Balster F, Gardley P, Ashbaugh L. Newborn screening for Krabbe disease-Illinois experience: Role of psychosine in diagnosis of the disease. Int J Neonatal Screen. 2021; 7: 24.